Pharmaceutical Shares of US specialty pharma company Baudax Bio were up more than 7% at $7.55 pre-market today, after it announced that the US Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. 22 January 2020